Switch theme
Sign up to access all valuation multiples
Shandong Buchang Pharmaceuticals Co Ltd is engaged in research and development, production and sales of Chinese patent medicines.
2001
8.3K+
LTM Revenue n/a
LTM EBITDA n/a
$2.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Buchang Pharma has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Buchang Pharma achieved revenue of $1.8B and an EBITDA of $151M.
Buchang Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Buchang Pharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.8B | n/a | XXX | XXX | XXX |
| Gross Profit | $1.6B | $1.5B | XXX | XXX | XXX |
| Gross Margin | 88% | NaN% | XXX | XXX | XXX |
| EBITDA | $151M | n/a | XXX | XXX | XXX |
| EBITDA Margin | 8% | NaN% | XXX | XXX | XXX |
| Net Profit | $160M | -$211M | XXX | XXX | XXX |
| Net Margin | 9% | NaN% | XXX | XXX | XXX |
| Net Debt | $273M | $85.0M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Buchang Pharma's stock price is CNY 15 (or $2).
Buchang Pharma has current market cap of CNY 16.2B (or $2.2B), and EV of CNY 18.7B (or $2.6B).
See Buchang Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.6B | $2.2B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Buchang Pharma has market cap of $2.2B and EV of $2.6B.
Buchang Pharma's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Buchang Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Buchang Pharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.6B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpBuchang Pharma's NTM/LTM revenue growth is n/a
Buchang Pharma's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Buchang Pharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Buchang Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Buchang Pharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 46% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 59% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Buchang Pharma acquired XXX companies to date.
Last acquisition by Buchang Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Buchang Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Buchang Pharma founded? | Buchang Pharma was founded in 2001. |
| Where is Buchang Pharma headquartered? | Buchang Pharma is headquartered in China. |
| How many employees does Buchang Pharma have? | As of today, Buchang Pharma has 8.3K+ employees. |
| Is Buchang Pharma publicy listed? | Yes, Buchang Pharma is a public company listed on SHG. |
| What is the stock symbol of Buchang Pharma? | Buchang Pharma trades under 603858 ticker. |
| When did Buchang Pharma go public? | Buchang Pharma went public in 2016. |
| Who are competitors of Buchang Pharma? | Similar companies to Buchang Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Buchang Pharma? | Buchang Pharma's current market cap is $2.2B |
| Is Buchang Pharma profitable? | Yes, Buchang Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
